BioSpace News Archive

Evotec SE and Alpine Immune Sciences, Inc. announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for the treatment of systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.

In situ hybridization refers to a well-established set of methods for the visualization and detection of specific nucleic acid sequences in whole organisms, cytological preparations, and tissue sections.

The world cardiovascular ultrasound system market is foretold to take the first flight to maintaining a substantial progress with innovations and collaborations encouraged globally.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The antisense oligonucleotides market is expected to gain extensive growth across the assessment period of 2020-2030.

The mounting cases of people suffering from respiratory disorders is the foremost factor driving the global respiratory diagnostics market.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Serum separation gel enables the stable and reliable separation of the blood clot and serum with low influence on the clinical results.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Remote healthcare is a telemedicine service that uses a mobile device to constantly monitor a patient’s condition and performance outside a medical facility.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global platelet-rich plasma market is expected to surpass an impressive valuation of around US $ 1.5 Billion surpassing a CAGR of 12% during the assessment period.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Advances in optical technologies continue to enrich biomedical research.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Koen van Besien as Medical Director.